Cypherpunk Technologies Inc (CYPH)

$1.00 +0.12 (13.69%)
Market Cap 79.15M
Revenue (ttm) 0.00
Net Income (ttm) 4.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,667,600
Avg Vol 2,163,702
Day's Range N/A - N/A
Shares Out 89.98M
Stochastic %K 75%
Beta -0.22
Analysts Strong Buy
Price Target N/A

Company Profile

Cypherpunk Technologies Inc., a privacy technology company, implements a digital asset strategy anchored by Zcash in the United States. The company is involved in identifying, developing, investing in, acquiring, and building privacy-enhancing technologies; and accumulating digital assets, such as ZCash. It also develops biomarker-targeted antibody therapies for patients with cancer and other diseases comprising DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which has co...

Industry: Asset Management
Sector: Financial Services
Phone: 617 714 0360
Address:
47 Thorndike Street, Suite B1-1, Cambridge, United States
PrincePuddle
PrincePuddle Apr. 25 at 9:56 PM
I made me 6k from his calls this month. He’s been Straight up dominating lately. Give him a FOLLOW❤️ Thank you @ApolloAlerts 🙏 $AMD $CYPH $CRML ~ on top of my wl for tomorrow!!
0 · Reply
PrincePuddle
PrincePuddle Apr. 25 at 8:51 PM
$CYPH looks ready for monday
0 · Reply
Ron_Burn
Ron_Burn Apr. 25 at 6:53 PM
$CYPH break 1.12 - 1.18 and it's one
1 · Reply
RoyalImperial
RoyalImperial Apr. 25 at 5:40 PM
MITQ ✅ Has that look for next week, one of the most undervalued and cleanest micro caps. Latest news + contracts rolling in Low float (6M) NO dilution Record earnings trend 📈. A $9M projector refresh contract plus other large projects shifting into FY2026 means a significant revenue surge is likely already locked in and coming. $GSIT $OSRH $NDLS $CYPH ww hot./ .1
0 · Reply
FamilyTime444
FamilyTime444 Apr. 25 at 1:18 PM
$CYPH
0 · Reply
atechniqueisause
atechniqueisause Apr. 25 at 12:38 AM
$CYPH
0 · Reply
Thedude2009
Thedude2009 Apr. 24 at 9:06 PM
$CYPH cancer drug news any day now
1 · Reply
atechniqueisause
atechniqueisause Apr. 24 at 8:54 PM
$CYPH
0 · Reply
automaticstatic
automaticstatic Apr. 24 at 7:16 PM
$CYPH $1 only give us $5 - thank you!
0 · Reply
SexyStockSlayer
SexyStockSlayer Apr. 24 at 7:04 PM
$CYPH Stay over a $1 lets go!
0 · Reply
Latest News on CYPH
Cypherpunk Increases its Zcash Stake, Launches New Website and Investor Dashboard

Apr 15, 2026, 12:21 PM EDT - 10 days ago

Cypherpunk Increases its Zcash Stake, Launches New Website and Investor Dashboard

Cypherpunk Reports Full Year 2025 Financial Results

Mar 16, 2026, 4:50 PM EDT - 5 weeks ago

Cypherpunk Reports Full Year 2025 Financial Results

Cypherpunk Makes $5M Investment into Zcash Open Development Lab (ZODL)

Mar 9, 2026, 9:20 AM EDT - 6 weeks ago

Cypherpunk Makes $5M Investment into Zcash Open Development Lab (ZODL)

Cypherpunk Adds Arjun Khemani as Strategic Advisor

Jan 22, 2026, 7:00 AM EST - 3 months ago

Cypherpunk Adds Arjun Khemani as Strategic Advisor

Cypherpunk Accelerates Zcash Accumulation; Increases Treasury Holdings to 290,062.67 ZEC

Dec 30, 2025, 7:00 AM EST - 4 months ago

Cypherpunk Accelerates Zcash Accumulation; Increases Treasury Holdings to 290,062.67 ZEC

Josh Swihart, ECC CEO, Joins Cypherpunk as Strategic Advisor

Dec 19, 2025, 7:00 AM EST - 4 months ago

Josh Swihart, ECC CEO, Joins Cypherpunk as Strategic Advisor

Cypherpunk Technologies Transcript: AGM 2025

Dec 15, 2025, 11:00 AM EST - 4 months ago

Cypherpunk Technologies Transcript: AGM 2025

Cypherpunk Taps Zcash Founder Zooko as Strategic Advisor

Dec 9, 2025, 7:00 AM EST - 4 months ago

Cypherpunk Taps Zcash Founder Zooko as Strategic Advisor

Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 8:00 AM EST - 5 months ago

Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results

Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy

Nov 12, 2025, 7:00 AM EST - 5 months ago

Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy

Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025

Oct 20, 2025, 7:00 AM EDT - 6 months ago

Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025

Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

Oct 9, 2025, 7:00 AM EDT - 7 months ago

Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

Oct 6, 2025, 9:00 AM EDT - 7 months ago

Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025

Sep 25, 2025, 7:00 AM EDT - 7 months ago

Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025

Leap Therapeutics Reports Second Quarter 2025 Financial Results

Aug 14, 2025, 7:00 AM EDT - 9 months ago

Leap Therapeutics Reports Second Quarter 2025 Financial Results

Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives

Jun 23, 2025, 7:00 AM EDT - 10 months ago

Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives

Leap Therapeutics Reports First Quarter 2025 Financial Results

May 13, 2025, 7:00 AM EDT - 1 year ago

Leap Therapeutics Reports First Quarter 2025 Financial Results

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

Apr 25, 2025, 1:00 PM EDT - 1 year ago

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

Cypherpunk Technologies Transcript: Status Update

Apr 23, 2025, 2:30 PM EDT - 1 year ago

Cypherpunk Technologies Transcript: Status Update

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

Apr 15, 2025, 7:00 AM EDT - 1 year ago

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

Mar 26, 2025, 1:29 PM EDT - 1 year ago

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 26, 2025, 7:05 AM EDT - 1 year ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

Mar 26, 2025, 7:00 AM EDT - 1 year ago

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

Cypherpunk Technologies Transcript: Study Result

Jan 28, 2025, 8:00 AM EST - 1 year ago

Cypherpunk Technologies Transcript: Study Result

Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

Jan 28, 2025, 7:00 AM EST - 1 year ago

Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

Cypherpunk Technologies Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 5:15 PM EST - 1 year ago

Cypherpunk Technologies Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 7:00 AM EST - 1 year ago

Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Cypherpunk Technologies Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 4, 2024, 4:00 PM EST - 1 year ago

Cypherpunk Technologies Transcript: Piper Sandler 36th Annual Healthcare Conference

Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 7:00 AM EST - 1 year ago

Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

Leap Therapeutics Reports Third Quarter 2024 Financial Results

Nov 13, 2024, 7:00 AM EST - 1 year ago

Leap Therapeutics Reports Third Quarter 2024 Financial Results

Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics Reports Second Quarter 2024 Financial Results

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Leap Therapeutics Reports Second Quarter 2024 Financial Results

Leap Therapeutics Reports First Quarter 2024 Financial Results

May 13, 2024, 7:00 AM EDT - 2 years ago

Leap Therapeutics Reports First Quarter 2024 Financial Results

Leap Therapeutics Announces $40 Million Private Placement

Apr 11, 2024, 8:30 AM EDT - 2 years ago

Leap Therapeutics Announces $40 Million Private Placement

Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 18, 2024, 7:00 AM EDT - 2 years ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Cypherpunk Technologies Transcript: Study Update

Jan 23, 2024, 8:30 AM EST - 2 years ago

Cypherpunk Technologies Transcript: Study Update

Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium

Jan 16, 2024, 5:05 PM EST - 2 years ago

Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium

Cypherpunk Technologies Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 10, 2024, 4:30 PM EST - 2 years ago

Cypherpunk Technologies Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 7:00 AM EST - 2 years ago

Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Jan 2, 2024, 7:00 AM EST - 2 years ago

Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium

Dec 11, 2023, 4:05 PM EST - 2 years ago

Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium

Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference

Nov 21, 2023, 7:00 AM EST - 2 years ago

Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference

Leap Therapeutics Reports Third Quarter 2023 Financial Results

Nov 13, 2023, 7:00 AM EST - 2 years ago

Leap Therapeutics Reports Third Quarter 2023 Financial Results

Leap Therapeutics to Participate at Upcoming Investor Conferences

Sep 5, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics to Participate at Upcoming Investor Conferences

Leap Therapeutics Reports Second Quarter 2023 Financial Results

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Reports Second Quarter 2023 Financial Results

Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients

Jul 12, 2023, 7:00 AM EDT - 3 years ago

Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients

Leap Therapeutics Announces Reverse Stock Split

Jun 20, 2023, 12:30 PM EDT - 3 years ago

Leap Therapeutics Announces Reverse Stock Split

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

May 25, 2023, 5:10 PM EDT - 3 years ago

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

Leap Therapeutics Reports First Quarter 2023 Financial Results

May 15, 2023, 7:00 AM EDT - 3 years ago

Leap Therapeutics Reports First Quarter 2023 Financial Results

Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Apr 12, 2023, 7:00 AM EDT - 3 years ago

Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 24, 2023, 7:00 AM EDT - 3 years ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01

Mar 16, 2023, 4:05 PM EDT - 3 years ago

Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01

Cypherpunk Technologies Transcript: M&A Announcement

Jan 17, 2023, 9:00 AM EST - 3 years ago

Cypherpunk Technologies Transcript: M&A Announcement

Leap Therapeutics Acquires Flame Biosciences

Jan 17, 2023, 8:00 AM EST - 3 years ago

Leap Therapeutics Acquires Flame Biosciences

Cypherpunk Technologies Transcript: R&D Day 2022

Jul 12, 2022, 12:00 PM EDT - 4 years ago

Cypherpunk Technologies Transcript: R&D Day 2022

Cypherpunk Technologies Transcript: Study Update

Jan 21, 2022, 1:00 PM EST - 4 years ago

Cypherpunk Technologies Transcript: Study Update

Cypherpunk Technologies Transcript: Study Update

Sep 17, 2021, 8:00 AM EDT - 5 years ago

Cypherpunk Technologies Transcript: Study Update

Cypherpunk Technologies Transcript: Study Update

Mar 22, 2021, 8:30 AM EDT - 5 years ago

Cypherpunk Technologies Transcript: Study Update

Cypherpunk Technologies Transcript: AGM 2020

Jun 16, 2020, 4:00 PM EDT - 6 years ago

Cypherpunk Technologies Transcript: AGM 2020

Cypherpunk Technologies Transcript: Study Update

Apr 23, 2020, 8:30 AM EDT - 6 years ago

Cypherpunk Technologies Transcript: Study Update

Cypherpunk Technologies Transcript: Study Update

Aug 6, 2019, 8:30 AM EDT - 7 years ago

Cypherpunk Technologies Transcript: Study Update

Cypherpunk Technologies Transcript: Study Update

Dec 17, 2018, 8:30 AM EST - 7 years ago

Cypherpunk Technologies Transcript: Study Update

Cypherpunk Technologies Transcript: Study Update

Oct 22, 2018, 8:00 AM EDT - 8 years ago

Cypherpunk Technologies Transcript: Study Update

PrincePuddle
PrincePuddle Apr. 25 at 9:56 PM
I made me 6k from his calls this month. He’s been Straight up dominating lately. Give him a FOLLOW❤️ Thank you @ApolloAlerts 🙏 $AMD $CYPH $CRML ~ on top of my wl for tomorrow!!
0 · Reply
PrincePuddle
PrincePuddle Apr. 25 at 8:51 PM
$CYPH looks ready for monday
0 · Reply
Ron_Burn
Ron_Burn Apr. 25 at 6:53 PM
$CYPH break 1.12 - 1.18 and it's one
1 · Reply
RoyalImperial
RoyalImperial Apr. 25 at 5:40 PM
MITQ ✅ Has that look for next week, one of the most undervalued and cleanest micro caps. Latest news + contracts rolling in Low float (6M) NO dilution Record earnings trend 📈. A $9M projector refresh contract plus other large projects shifting into FY2026 means a significant revenue surge is likely already locked in and coming. $GSIT $OSRH $NDLS $CYPH ww hot./ .1
0 · Reply
FamilyTime444
FamilyTime444 Apr. 25 at 1:18 PM
$CYPH
0 · Reply
atechniqueisause
atechniqueisause Apr. 25 at 12:38 AM
$CYPH
0 · Reply
Thedude2009
Thedude2009 Apr. 24 at 9:06 PM
$CYPH cancer drug news any day now
1 · Reply
atechniqueisause
atechniqueisause Apr. 24 at 8:54 PM
$CYPH
0 · Reply
automaticstatic
automaticstatic Apr. 24 at 7:16 PM
$CYPH $1 only give us $5 - thank you!
0 · Reply
SexyStockSlayer
SexyStockSlayer Apr. 24 at 7:04 PM
$CYPH Stay over a $1 lets go!
0 · Reply
AtomicTradesPennyStocks
AtomicTradesPennyStocks Apr. 24 at 6:14 PM
Here is my 2:15pm radar list: $CYPH for $1.10, $CREG for $.80S, $NXXT for $.50S, $SOUN calls for $9S and $GUTS for $.70S. Live trading here with me for "Power Hour" for all https://app.ragingbull.com/room/the-war-room
0 · Reply
automaticstatic
automaticstatic Apr. 24 at 5:57 PM
$CYPH a lot of volume today! Anyone have any insight on why?
0 · Reply
SexyStockSlayer
SexyStockSlayer Apr. 24 at 5:55 PM
$ZEC.X been accumulating as much ZEC and $CYPH as I can! ZEC to $1000
0 · Reply
Hegotgame88
Hegotgame88 Apr. 24 at 5:50 PM
$ZEC.X $CYPH
0 · Reply
luminouslumens
luminouslumens Apr. 24 at 5:48 PM
$CYPH 💥
0 · Reply
automaticstatic
automaticstatic Apr. 24 at 5:39 PM
$CYPH wow this is looking strong... any ideas on price target? And why is it moving?
0 · Reply
Ron_Burn
Ron_Burn Apr. 24 at 4:42 PM
$CYPH still building it's base. Maybe it will breakout next week
2 · Reply
automaticstatic
automaticstatic Apr. 24 at 3:58 PM
$CYPH give us a run to $4 or $5 please. Thanks!
2 · Reply
atechniqueisause
atechniqueisause Apr. 24 at 12:06 PM
$CYPH
0 · Reply
Walter100
Walter100 Apr. 24 at 2:42 AM
$CYPH
0 · Reply
Walter100
Walter100 Apr. 24 at 1:07 AM
$CYPH I’m happy with a +100% from here in 3-4 months. IMO, many factors aligning: Tachyon upgrade Grayscale spot $ZEC.X ETF Robinhood listing ZEC Foundry mining ZODL wallet default auto shielding of ZEC Increasing concern about surveillance ZEC’s pure cryptography based privacy Viewing keys making ZEC privacy regulatory friendly
0 · Reply
StockThingzs02
StockThingzs02 Apr. 23 at 10:41 PM
$AMD strong after hours $CYPH
0 · Reply